-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026IND filing for the Enhanced Brain Delivery™ (EBD®)
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Two candidates nominated for development in Acumen’s
NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that
EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the
- Strategic partnership, announced in July 2025, utilizes JCR's J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer's disease
- Option exercise
ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR PharmaceuticalsEBD technology represents the only anti-amyloid oligomer program
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's EBDTM
NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for
NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble
